Painless Botox(r) Type Cream Patent Approved

KING OF PRUSSIA, Pa., Nov. 12, 2008 (GLOBE NEWSWIRE) — Emergent Health Corp. (Pink Sheets:EMGE) announces the patent under which it has a license to market a painless Botox(r) type cream not requiring an injection has been allowed by the US Patent and Trademark office. Now that this patent has been allowed, Emergent will seek joint venture opportunities with firms capable of assisting entry into this estimated $6 Billion dollar cosmetic market.

While Botox(r) Cosmetic as a registered trademark of Allergan and Restylane(r) Dermal Filler as a registered trademark of Medicis are the dominant leaders in pharmaceutical cosmetic delivery, Emergent believes there is a viable and sizeable niche for its Painless BO(tm) Cream with the appropriate partners. Emergent plans to aggressively pursue this opportunity. Emergent believes there is a possibility Painless BO(tm) Cream could not only make penetration into the large currently available markets but also open totally new markets for those who still fear needles and the high costs of Physician visits so associated.

Emergent is also making further strides in the introduction of all of its current products, Hungarest(tm) Diet Aid http://www.appetitecontrolled.com and Vita-Stim(tm) Life Enhancement http://www.vita-stim.com. It also introduced a new product for Physician only dispensing Neuvitale(tm) Life Support http://www.neuvitale.com.

Emergent engages in the discovery, development and marketing of products designed to better mankind. Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Emergent is focusing current efforts on marketing licensed patent pending natural stem cell propagating agents capable of enhancing each individual’s ability to increase their own adult stem cells from their bone marrow and under a patent pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Emergent was founded in 2006 and is now headquartered in King of Prussia, PA.

This press release contains certain “forward-looking” statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

CONTACT:  Emergent Health Corp.
          John Vincent
          866-427-6143
          20104 Valley Forge Circle
          King of Prussia, PA 19406